What has been Mylan's strategy for its ARV range, considering that there are already established players (such as Cipla) in this segment?
In the next five years, our goal will be to build Mylan's brand equity in India and position ourselves as a high quality, innovative and cutting edge pharmaceutical company with global standards. In the long-term, we aim to be a top 10 company in India.

While we understand that we will be entering a highly competitive market, the key to differentiating ourselves from local players and other MNCs is by educating Indian physicians, pharmacists, customers and consumers about what the Mylan brand stands for: unmatched supply reliability, outstanding customer service, operational integrity and high quality products. Our sales force will be another key differentiator. We have hired what we believe is the best talent and have provided them with world class training to empower them to be Mylan's brand ambassadors in India

Moving ahead, what are your plans about releasing the rest of the products in the Mylans' ARV 43 ARV drug portfolio?
In the first phase we have made available a comprehensive range of 18 products from our HIV division portfolio available in the Indian market. We are looking at the market requirement and depending on its need we will continue to launch other products from our ARV portfolio.

Mylan expects to launch product portfolios in additional therapeutic categories, such as women's health care and oncology, in the future. We will provide more details on these plans and the number and types of products as we launch those therapeutic categories.

Can you describe development of innovations in these drugs such as heat stable ARV products, combo blister packs ?
Innovation is one of Mylan's core values and we are constantly looking at ways to innovate across our product portfolio, as we have done with ARVs, and we will seek to bring to the Indian market additional innovative, market-appropriate products in other therapeutic categories over time.

Mylan also has introduced a number of ARV innovations, for instance producing single blister "combo" packs, which provide a reduced pill burden and once-a-day dosage. Mylan also developed three FDA/WHO-approved heat-stable ARV products, which can be distributed and used in countries where refrigeration infrastructure is not widely available. In addition, Mylan has been a global leader in producing ARV formulations for pediatric use.

Are there any patient access programs currently in place for the ARV drugs?
For its ARV business, Mylan is targeting ARV specialists with its sales force and will have one of the largest field forces exclusively specializing in HIV/AIDS in India. Through specialists, we believe we will be able to reach the majority of our target patient population. Mylan will deploy a multi pronged distribution to ensure that medicines are accessible where they are needed, which will include through doctors, NGOs, pharmacists and bodies such as the National Aids Control Organization (NACO). Our objective is to reach these therapies wherever there are HIV patients and we are evaluating a number of other programs to enhance access.

Can you elaborate on the efforts that Mylan has taken to expand its existing infrastructure in India?
Our commercial launch in India is one of Mylan's strategic growth drivers and we intend to invest in the business appropriately to support its success. Globally, Mylan is investing $1.4 billion in CapEx and $2 billion in R&D to support our growth. We expect to increase our manufacturing capacity in the Asia Pacific region from 17 billion doses today to 50 billion doses in 2012. Much of this expansion is expected to be in India.